Search clinical trials for: BI 11634 ER formulation C

Total 150 results

Boehringer Ingelheim

Completed

Bioavailability of Four Oral Prototype Extended Release Formulations With BI 11634 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 685509 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Pharmacokinetics and Relative Bioavailability of 11634 Immediate Release Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 11634 Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Active, not recruiting

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Solid Tumors

Hungary
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1810631 is Taken up and Processed by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple, Rising Oral Doses of BI 11634 Oral Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body

Healthy

United Kingdom
Boehringer Ingelheim

Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Small Cell Lung Carcinoma | Neuroendocrine Neoplasms

United States, Belgium, Spain, Korea, Republic of, United Kingdom, Germany, Japan, China, Taiwan, France, Portugal, Bulgaria
Boehringer Ingelheim

Not yet recruiting

A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body

Healthy
AstraZeneca

Completed

To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers

Parkinson's Disease

United Kingdom
Boehringer Ingelheim

Terminated

Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects

Healthy
Boehringer Ingelheim

Completed

A Study in Healthy People to Compare 2 Different Formulations of BI 1358894 Tablets Taken With or Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without Food

Healthy

Germany
GlaxoSmithKline

Completed

Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients

Multiple Sclerosis

Poland, Germany, Czechia
Lyndra Inc.

Completed

Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules in Healthy Adults

Healthy | Gastric Retention

Australia
Vertex Pharmaceuticals Incorporated

Completed

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

Chronic Hepatitis C

United States
Boehringer Ingelheim

Completed

Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body

Healthy

Netherlands
ViiV Healthcare

Recruiting

A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants

HIV Infections

United Kingdom
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
Pfizer

Terminated

A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults

Respiratory Tract Infection

United States, Australia
Boehringer Ingelheim

Completed

Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet

Healthy

Netherlands
Pfizer

Recruiting

Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults

Healthy Subjects | Healthy Participants

United States
Pfizer

Completed

A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants

Healthy

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Pfizer

Active, not recruiting

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons. It Will Be Given Twice Over a Period of Time to Healthy Adults

Clostridoides Difficile Associated Disease

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Find Out How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
Bristol-Myers Squibb

Completed

A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants

Heart Failure

United States
ViiV Healthcare
GlaxoSmithKline

Not yet recruiting

First Time in Human Study of Long Acting VH4524184 Formulations

HIV Infections

United States
GlaxoSmithKline

Completed

Bioequivalence and Food Effect Study in Healthy Volunteers

Sleep Initiation and Maintenance Disorders

Italy
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 456906 is Processed in the Body

Healthy

Netherlands
Allergan

Completed

A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects

Healthy Volunteers

United States
Allergan

Completed

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

Erythema | Rosacea

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood

Healthy

Belgium
Janssen Sciences Ireland UC

Completed

Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants

Healthy

United Kingdom
Cartiheal (2009) Ltd

Completed

Evaluation of the Agili-C Biphasic Implant in the Knee Joint

Cartilage Diseases | Osteochondritis Dissecans

Czechia, Italy, Croatia, Hungary, Poland, Romania, Serbia, Slovenia
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 764198 is Processed in the Body

Healthy

Netherlands
Allergan

Completed

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

Alopecia | Alopecia, Androgenetic | Baldness

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet

Healthy

Netherlands
AstraZeneca
Parexel

Completed

A Study to Assess the Amount of Drug Levels in Blood and Safety of AZD5718 Formulations in Healthy Volunteers

Coronary Artery Disease (CAD)

United Kingdom
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How the Body Takes up BI 1467335

Healthy

Netherlands
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects

Healthy Volunteers

Germany
Mylan Inc.
Mylan GmbH

Completed

Mylan Insulin Glargine Study

Diabetes Mellitus, Type 1

United States
Boehringer Ingelheim

Completed

Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers

Healthy
Val Lowe

Enrolling by invitation

Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia

Alzheimer Disease

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1291583 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 730357 is Processed by the Body

Healthy

Netherlands

3

Subscribe